martes, 25 de octubre de 2016

Chronic Lymphocytic Leukemia Treatment (PDQ®)—Health Professional Version - National Cancer Institute

Chronic Lymphocytic Leukemia Treatment (PDQ®)—Health Professional Version - National Cancer Institute

National Cancer Institute

Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version



SECTIONS



Changes to This Summary (10/21/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Revised text to state that in the absence of randomized trials comparing the new B-cell receptor inhibitors and bcl-2 inhibitors to the new monoclonal antibodies and to more conventional chemotherapeutic agents, some general principles may provide a sequencing for available therapeutic options. Options were listed.
This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
  • Updated: October 21, 2016

No hay comentarios:

Publicar un comentario